Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?

BACKGROUND: Bevacizumab (Bev) has gained acceptance as an active agent in the treatment of epithelial ovarian cancer (EOC). Data is lacking on survival outcomes in patients who are re-treated with Bev after achieving a complete response to a Bev-containing regimen (BCR). Our primary objective was to...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Main Authors:	McCann, Georgia A., Smith, Blair, Backes, Floor J., Rath, Kellie, Chacko, Simi, Salani, Ritu, Eisenhauer, Eric, Fowler, Jeffrey, Cohn, David, Copeland, Larry, O’Malley, David
Format:	Artigo
Sprog:	Inglês
Udgivet:	2012
Fag:	Article
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3886294/ https://ncbi.nlm.nih.gov/pubmed/22885866 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2012.08.001
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?

Lignende værker